Compare UFG & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | HOWL |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Singapore | United States |
| Employees | 17 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 30.7M |
| IPO Year | N/A | 2021 |
| Metric | UFG | HOWL |
|---|---|---|
| Price | $0.90 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 305.2K | ★ 395.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.40 | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.53 |
| 52 Week High | $9.91 | $2.23 |
| Indicator | UFG | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 60.04 |
| Support Level | $0.78 | $0.81 |
| Resistance Level | $1.29 | $1.03 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 16.00 | 76.20 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.